In the past week, BMY stock has gone up by 3.46%, with a monthly gain of 4.06% and a quarterly surge of 25.28%. The volatility ratio for the week is 2.70%, and the volatility levels for the last 30 days are 2.33% for Bristol-Myers Squibb Co. The simple moving average for the last 20 days is 4.29% for BMY stock, with a simple moving average of 8.41% for the last 200 days.
Is It Worth Investing in Bristol-Myers Squibb Co. (NYSE: BMY) Right Now?
BMY has 36-month beta value of 0.46. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 5 as “overweight,” 11 as “hold,” and 2 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BMY is 2.03B, and currently, short sellers hold a 1.08% ratio of that float. The average trading volume of BMY on October 01, 2024 was 13.74M shares.
BMY) stock’s latest price update
Bristol-Myers Squibb Co. (NYSE: BMY) has seen a rise in its stock price by 1.63 in relation to its previous close of 50.91. However, the company has experienced a 3.46% gain in its stock price over the last five trading sessions. reuters.com reported 2024-09-30 that Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for the cancer drug Breyanzi and two other drugs developed by Celgene.
Analysts’ Opinion of BMY
Many brokerage firms have already submitted their reports for BMY stocks, with Barclays repeating the rating for BMY by listing it as a “Equal Weight.” The predicted price for BMY in the upcoming period, according to Barclays is $41 based on the research report published on July 29, 2024 of the current year 2024.
Redburn Atlantic gave a rating of “Neutral” to BMY, setting the target price at $54 in the report published on February 06th of the current year.
BMY Trading at 6.94% from the 50-Day Moving Average
After a stumble in the market that brought BMY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.50% of loss for the given period.
Volatility was left at 2.33%, however, over the last 30 days, the volatility rate increased by 2.70%, as shares surge +3.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +21.34% upper at present.
During the last 5 trading sessions, BMY rose by +3.46%, which changed the moving average for the period of 200-days by +2.44% in comparison to the 20-day moving average, which settled at $49.70. In addition, Bristol-Myers Squibb Co. saw 0.84% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BMY starting from BOERNER CHRISTOPHER S., who purchase 2,000 shares at the price of $49.78 back on Dec 05 ’23. After this action, BOERNER CHRISTOPHER S. now owns 82,672 shares of Bristol-Myers Squibb Co., valued at $99,560 using the latest closing price.
BOERNER CHRISTOPHER S., the Chief Executive Officer of Bristol-Myers Squibb Co., purchase 3,071 shares at $48.86 during a trade that took place back on Nov 28 ’23, which means that BOERNER CHRISTOPHER S. is holding 79,384 shares at $150,049 based on the most recent closing price.
Stock Fundamentals for BMY
Current profitability levels for the company are sitting at:
- 0.27 for the present operating margin
- 0.71 for the gross margin
The net margin for Bristol-Myers Squibb Co. stands at -0.14. The total capital return value is set at 0.17. Equity return is now at value -26.70, with -6.95 for asset returns.
Based on Bristol-Myers Squibb Co. (BMY), the company’s capital structure generated 0.76 points at debt to capital in total, while cash flow to debt ratio is standing at 0.27. The debt to equity ratio resting at 3.09. The interest coverage ratio of the stock is 8.01.
Currently, EBITDA for the company is 19.18 billion with net debt to EBITDA at 2.66. When we switch over and look at the enterprise to sales, we see a ratio of 3.28. The receivables turnover for the company is 3.07for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.16.
Conclusion
To put it simply, Bristol-Myers Squibb Co. (BMY) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
